Navigation Links
Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/13/2009

Contacts: Transcept Pharmaceuticals, Inc. The Ruth Group Michael Gill Investors / Media Director of Communications Stephanie Carrington / Jason Rando (510) 215-3575 (646) 536-7017 / 7025 mgill@transcept.com scarrington@theruthgroup.com jrando@theruthgroup.com

                                  FINANCIAL TABLES FOLLOW

    Transcept Pharmaceuticals, Inc.
    Statements of Operations
    (Unaudited)
                                                          Period From
                                Three Months Ended         Inception
                                     March 31,         (January 8, 2002)
                                  2009         2008    to March 31, 2009
    Operating expenses:
      Research and
       development            $2,221,884   $3,610,595        $45,549,285
      General and
       administrative          4,213,770    1,512,368         25,206,493
      Merger related
       transaction costs       2,223,860            -          4,190,623
    Total operating expenses   8,659,514    5,122,963         74,946,401
    Loss from operations      (8,659,514)  (5,122,963)       (74,946,401)
    Interest income               87,735      336,184          3,919,791
    Interest expense            (165,658)    (236,842)        (2,531,305)
    Other income (expense),
     net                         199,673      (48,715)           443,913
    Interest expense related to
     bridge loan warrants              -            -           (535,195)
    Net loss                  (8,537,764)  (5,072,336)       (73,649,197)
    Deemed dividend -
     Series C convertible
     preferred stockholders            -            -           (457,874)
    
'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Transcept Pharmaceuticals Appoints Joseph T. Kennedy as General Counsel
2. Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results
3. Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results
4. Transcept Pharmaceuticals to Present at Two Upcoming Conferences
5. Transcept Pharmaceuticals, Inc. Completes Merger with Novacea, Inc.
6. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
7. Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
8. Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
9. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
10. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
11. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... September 30, 2014 World of Children ... founder of the nonprofit, Friends Without A Border (FWAB) ... for building a hospital in Cambodia that has become ... Izu first encountered Cambodia’s appalling lack of pediatric healthcare ... disabilities and illnesses during a photography trip in 1993. ...
(Date:9/30/2014)... 30, 2014 During this online ... approaches to health including achieving hormonal balance, relieving ... and detoxification. , The details ... Date: October 6-9, 2014, Location: Online Event, Registration: ... http://www2.hotzehwc.com/naturalhealthsummitregistration , Monday, October 6th, Steven F. ...
(Date:9/30/2014)... September 30, 2014 AutoTex PINK ... the iconic pink ribbon in support of breast cancer ... month for businesses and non-profits to “go pink” -- ... , AutoTex PINK is a woman-owned company that is ... They are committed to partnering with their customers to ...
(Date:9/30/2014)... September 30, 2014 Timber Home Living Magazine ... for the Olsen family’s reclaimed Douglas fir timber frame home ... home’s journey from architectural planning, to the frame raising, to ... to New Energy Works, after following the timber framing company ... build their dream vacation home on land they fell in ...
(Date:9/30/2014)... Oxnard, CA (PRWEB) September 30, 2014 ... the Anacapa Dental Art Institute in Oxnard and Thousand ... Bangalore today and tomorrow to provide training on full ... previous dental work, placing implants, providing cosmetic dentistry, correcting ... Dr. Jivraj said. , Dr. Jivraj, who has traveled ...
Breaking Medicine News(10 mins):Health News:Nobel Prize For Child Advocates Announces 2014 Health Award Honoree 2Health News:Nobel Prize For Child Advocates Announces 2014 Health Award Honoree 3Health News:Hotze Health & Wellness Center Announces First Natural Health Summit 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:Reclaimed Timber Frame Home By New Energy Works Featured in Timber Home Living Magazine 2Health News:Reclaimed Timber Frame Home By New Energy Works Featured in Timber Home Living Magazine 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 4Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 5
... 27 (HealthDay News) -- Arizona Congresswoman Gabrielle Giffords began ... forward for the lawmaker who was shot in the ... Memorial Hermann Hospital could last several months. As a ... insert a valve into her breathing tube, the ...
... January 27, 2011 Screening patients in the intensive ... cost savings for the whole hospital, according to a ... the February issue of the American Journal of ... the Association for Professionals in Infection Control and Epidemiology. ...
... , THURSDAY, Jan. 27 (HealthDay News) -- Only 42 ... and can therefore be categorized as "great sleepers," according to ... Poll" found that great sleepers get an average of about ... sleeper gets an average of seven hours and nine minutes ...
... News) -- Electroshock devices, currently classified by the U.S. Food ... severe depression, could be downgraded to medium risk this year. ... to discuss reclassifying the devices, which would pave the way ... illnesses. , , A medium-risk classification would put the devices ...
... continue dating a girlfriend who has cheated on them with ... according to new research from a University of Texas at ... are more likely to continue dating a man who has ... homosexual affair. The study, published last month in the ...
... in China have demonstrated interferon-alpha (IFN-a) is associated with ... erythematosus (SLE). For the first time, IFN-a priming was ... crucial step in plaque build-up. This activation of the ... atherosclerosis risk in SLE. Full findings of this novel ...
Cached Medicine News:Health News:Rep. Giffords' Intensive Rehab Under Way 2Health News:Rep. Giffords' Intensive Rehab Under Way 3Health News:Study finds MRSA screening saves hospitals money 2Health News:Loving Your Bedroom May Be Key to Good Sleep 2Health News:FDA May Ease Up on Electroshock Devices 2Health News:FDA May Ease Up on Electroshock Devices 3Health News:Men more likely to stick with girlfriends who sleep with other women than other men 2Health News:Researchers uncover link to increased atherosclerosis risk in lupus patients 2
(Date:9/30/2014)... , Sept. 30, 2014 CytRx Corporation ... and development company specializing in oncology, today announced ... trial evaluating aldoxorubicin compared to topotecan in subjects ... have relapsed or were refractory to prior chemotherapy. ... chemotherapeutic agent, doxorubicin. CytRx has received Orphan Drug ...
(Date:9/29/2014)... and PARIS , Sept. ... and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced ... investigational therapy that blocks IL-4 and IL-13 signaling, met ... chronic sinusitis with nasal polyps (CSwNP) who did not ... suggest the potential of dupilumab for use in the ...
(Date:9/29/2014)... et SAN DIEGO , ... Ltd. (ci-après désignée Daiichi Sankyo) (TSE : 4568) et ... la conclusion d,un accord de fusion définitif en ... totalité des actions ordinaires en circulation d,Ambit Biosciences ... le biais d,une offre publique d,achat qui sera ...
Breaking Medicine Technology:CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 2Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 3Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 4Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 6Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 7Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9
Used with T-tubes to collect drainage after cholecystectomy. Includes T-tube adapter and two adjustable latex rubber belts....
Used following open gallbladder procedure to drain bile. Often attached to Bard bile bag....
Silicone Flat Hubless Drains...
Bard® Channel Drain...
Medicine Products: